High dietary daidzein intake lowers cholesterol levels among post-menopausal women

Main Article Content

Elly Herwana
Pusparini Pusparini
Audria Graciela


Menopause is associated with changes in metabolic profile. Although hormone replacement therapy (HRT) has been shown to have beneficial effects on lipid metabolism, its adverse effects have indicated a need for alternative estrogen-based treatments. Several investigations have evaluated the effects of isoflavones on serum lipid levels in postmenopausal women, but the results were ambiguous. The objective of this study was to determine the relationship of dietary daidzein, genistein, and glycitein levels with lipid profile in postmenopausal women.

A cross-sectional study was conducted involving 186 post-menopausal women. A food recall questionnaire was used to measure dietary genistein, daidzein, and glycitein levels. Serum total cholesterol (TC), low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triacylglycerol (TAG) were measured using the enzymatic colorimetric method. Simple and multivariate linear regression were used to analyze the data.

Genistein intake was significantly associated with TC (b=145.48, p=0.023) and HDL cholesterol levels (b=48.80, p=0.032). Daidzein intake was significantly associated with TC (b=-204.60, p=0.003), LDL cholesterol (b=-160.81, p=0.014) and HDL cholesterol levels (b=-67.118, p=0.032). Glycitein was not significantly associated with TC (b=232.78;p=0.133), HDL (b=43.59;p=0.428), and LDL (b=235.84;p=0.116). Dietary daidzein had a more lowering effect on TC (Beta=-2.80) and HDL cholesterol (Beta=-2.67) than had genistein on TC (Beta=2.66) and HDL cholesterol (Beta=2.03).

High dietary daidzein level has a significant lowering effect on TC, LDL cholesterol and HDL cholesterol in post-menopausal women. Our study supports the advice given to the public to increase soy isoflavone intake in post-menopausal women.

Article Details

How to Cite
Herwana, E., Pusparini, P., & Graciela, A. (2020). High dietary daidzein intake lowers cholesterol levels among post-menopausal women. Universa Medicina, 39(1), 47–54. https://doi.org/10.18051/UnivMed.2020.v39.47-54
Original Articles


Ueda K, Adachi Y, Fukuma N, Takimoto E. Regulatory actions of estrogen receptor signaling in the cardiovascular system. Front Endocrinol 2020;10. Article 10:909. Doi: 10.3389/fendo.2019.00909.

Newson L. Menopause and cardiovascular disease. Post Reprod Health 2018;24:44-9. Doi: 10.1177/2053369117749675.

Pardhe BD, Ghimire S, Shakya J, et al. Elevated cardiovascular risk among postmenopausal women: a community based case control study from Nepal. Biochem Res Int 2017. Article ID 3824903, 5 pages. Doi: 10.1155/2017/3824903.

Zou H, Zhang C, Ni J, Han X. Prevalence of cardiovascular risk factors in non- menopausal and postmenopausal inpatients with type 2 diabetes mellitus in China. BMC Endocr Disord 2019;92:98, 9 pages. Doi: 10.1186/s12902-019-0427-7.

Zou Y, Wang D, Yang X, et al. Effect of menopausal status on carotid intima-media thickness and the presence of carotid plaque in Chinese women generation population. Scientific Reports 2015;5:8076, 5 pages. Doi: 10.1038/srep08076.

de Kat AC, Dam V, Onland-Moret NC, Eijkmans MJC, Broekmans FJM, van der Schouw YT. Unraveling the associations of age and menopause with cardiovascular risk factors in a large population-based study. BMC Medicine 2017;15:2, 11 pages. Doi: 10.1186/s12916-016-0762-8.

Lorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Difference 2017;8:33, 16 pages. Doi: 10.1186/s13293-017-0152-8.

Mansson JE, Chlebowski RT, Stefanick ML, et al. The Woman’s Health Initiative hormone therapy trials: update and overview of health outcomes during the intervention and post-stopping phases. JAMA 2013;310:1353-68. Doi: 10.1001/jama.2013.278040.

Roehm E. A reappraisal of Women’s Health Initiative Estrogen-Alone trial: Long term outcomes in women 50-59 years of age. Obstet Gynecol Int 2015, Article ID 713295, 10 pages. Doi: 10.1155/2015/713295.

Vergne S, Sauvant P, Lamothe V, et al. Influence of ethnic origin (Asian v. Caucasian) and background diet on the bioavailability of dietary isoflavones. Br J Nutr 2009;102:1642-53. Doi: 10.1017/S0007114509990833.

Pabrich M, Materska M. Biological effect of soy isoflavones in the prevention of civilization diseases. Nutrients 2019;1,1660, 13 pages. Doi:10.3390/nu11071660.

Wang Q, Ge X, Tian X, Zhang Y, Zhang P. Soy isoflavone: the multipurpose phytochemical. Biomedical Reports 2013:1;697-701. Doi: 10.3892/br.2013.129.

Ramdath DD, Padhi EMT, Sarfaraz S, Renwick S, Duncan AM. Beyond the cholesterol-lowering effect of soy protein: A review of the effects of dietary soy and its constituents on risk factors for cardiovascular disease. Nutrients 2017;9:324, 25 pages. doi:103390/nu9040324.

Patel RP, Barnes S. Isoflavones and PPAR signaling: a critical target in cardiovascular, metastatic, and metabolic disease. PPAR Res 2010. Article ID 153252, 10 pages. doi:10.1155/2010/153252.

Terzic M, Micic J, Dotlic J, Maricic S, Mihailovic T, Knezevic N. Impact of phytoestrogens on serum lipids in postmenopausal women. Geburtshilfe Frauenheilkd 2012;72:527–31. doi: 10.1055/s-0031-1298624.

Tokede OA, Onabanjo TA, Yansane A, Gaziano JM, Djoussé L. Soya products and serum lipid: a meta-analysis of randomized controlled trials. Br J Nutr 2015;114:831-4. Doi: 10.1017/S0007114515002603.

Jassi HK, Jain A, Arora S, Chitra R. Effect of soy proteins vs soy isoflavones on lipid profile in postmenopausal women. Indian J Clin Biochem 2010; 25: 201-7.

Kemenetrian Kesehatan. Status gizi dewasa menurut indeks massa tubuh: Riset kesehatan dasar (Riskesdas) 2010. Jakarta : Badan Penelitian and Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia;2013.

Santo AS, Santo AM, Browne RW, et al. Postprandial lipemia detects the effect of soy protein on cardiovascular disease risk compared with the fasting lipid profile. Lipids 2010;45:1127-38. Doi: 10.1007/s11745-010-3487-z.

Yenny, Pusparini. Isoflavone supplementation reduces low-density lipoprotein cholesterol levels in postmenopausal women. Univ Med 2013;32:197-207.

Herwana E, Setiabudy R, Soegondo S, et al. Soy isoflavone supplementation increases equol-producing capability in postmenopausal women with osteopenia. Univ Med 2012;31:120-30.

Chilibeck PD, Vatanparast H, Pierson R, et al. Effect of training combined with isoflavone supplementation on bone and lipids in postmenopausal women: A randomized clinical trial. J Bone Min Res 2013;28:780-93. Doi: 10.1002/jbmr.1815.

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) and reduction of vasomotor symptoms associated with menopause. EFSA J 2012;10:2847. doi:10.2903/j.efsa.2012.2847.

Messina M. Soy and health update: Evaluation on the clinical and epidemiologic literature. Nutrients 2016;8:754. 42 pages. Doi: 10.3390/nu8120754.